Predicting the diagnosis of autism in adults using the Autism-Spectrum Quotient (AQ) questionnaire by Ashwood, K. L. et al.
                          Ashwood, K. L., Gillan, N., Horder, J., Hayward, H., Woodhouse, E.,
Mcewen, F. S., ... Murphy, D. G. (2016). Predicting the diagnosis of autism
in adults using the Autism-Spectrum Quotient (AQ) questionnaire.
Psychological Medicine, 46(12), 2595-2604.
https://doi.org/10.1017/S0033291716001082
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1017/S0033291716001082
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Cambridge
University Press at https://www.cambridge.org/core/journals/psychological-medicine/article/predicting-the-
diagnosis-of-autism-in-adults-using-the-autismspectrum-quotient-aq-
questionnaire/CA0A8294A3494C7F60C166025914294C . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Predicting the diagnosis of autism in adults using
the Autism-Spectrum Quotient (AQ) questionnaire
K. L. Ashwood1,2†, N. Gillan1†, J. Horder1*†, H. Hayward1, E. Woodhouse1, F. S. McEwen2,3,4,5,
J. Findon1, H. Eklund1, D. Spain1,2, C. E. Wilson1,2,6, T. Cadman1, S. Young7, V. Stoencheva1,2,
C. M. Murphy1,2, D. Robertson2, T. Charman8, P. Bolton4, K. Glaser9, P. Asherson4, E. Simonoff3 and
D. G. Murphy1,2
1Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
2South London and Maudsley National Health Service Foundation Trust (SLAM), Maudsley Hospital, London, UK
3Child & Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
4Social, Genetic & Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
5Biological and Experimental Psychology, School of Biological and Chemical Sciences, Queen Mary University of London, London, UK
6 Individual Differences, Language and Cognition Laboratory, Department of Developmental and Educational Psychology, University of Seville,
Seville, Spain
7Centre for Mental Health, Imperial College London, London, UK
8Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
9Department of Social Science, Health & Medicine, School of Social Science & Public Policy, King’s College London, London, UK
Background. Many adults with autism spectrum disorder (ASD) remain undiagnosed. Specialist assessment clinics en-
able the detection of these cases, but such services are often overstretched. It has been proposed that unnecessary refer-
rals to these services could be reduced by prioritizing individuals who score highly on the Autism-Spectrum Quotient
(AQ), a self-report questionnaire measure of autistic traits. However, the ability of the AQ to predict who will go on to
receive a diagnosis of ASD in adults is unclear.
Method. We studied 476 adults, seen consecutively at a national ASD diagnostic referral service for suspected ASD. We
tested AQ scores as predictors of ASD diagnosis made by expert clinicians according to International Classiﬁcation of
Diseases (ICD)-10 criteria, informed by the Autism Diagnostic Observation Schedule-Generic (ADOS-G) and Autism
Diagnostic Interview-Revised (ADI-R) assessments.
Results. Of the participants, 73% received a clinical diagnosis of ASD. Self-report AQ scores did not signiﬁcantly predict
receipt of a diagnosis. While AQ scores provided high sensitivity of 0.77 [95% conﬁdence interval (CI) 0.72–0.82] and
positive predictive value of 0.76 (95% CI 0.70–0.80), the speciﬁcity of 0.29 (95% CI 0.20–0.38) and negative predictive
value of 0.36 (95% CI 0.22–0.40) were low. Thus, 64% of those who scored below the AQ cut-off were ‘false negatives’
who did in fact have ASD. Co-morbidity data revealed that generalized anxiety disorder may ‘mimic’ ASD and inﬂate
AQ scores, leading to false positives.
Conclusions. The AQ’s utility for screening referrals was limited in this sample. Recommendations supporting the AQ’s
role in the assessment of adult ASD, e.g. UK NICE guidelines, may need to be reconsidered.
Received 20 October 2015; Revised 18 April 2016; Accepted 21 April 2016; First published online 29 June 2016
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Introduction
Autism spectrum disorders (ASD) are a family of life-
long neurodevelopmental syndromes with a preva-
lence of at least 1% (Baird et al. 2006; Baron-Cohen
et al. 2009; Brugha et al. 2011a; Developmental
Disabilities Monitoring Network Surveillance Year
2010 Principal Investigators, 2014). In the UK, it is esti-
mated that each case of ASD is associated with average
total lifetime costs of nearly £1 million (Buescher et al.
2014). Early and accurate diagnosis of ASD is crucial to
enable affected individuals to receive treatment and
support (Koegel et al. 2014). Nonetheless, ASD fre-
quently goes undiagnosed into adulthood, which
causes avoidable distress and morbidity (Geurts &
Jansen, 2012; Nylander et al. 2013). Indeed, undiag-
nosed ASD is increasingly recognized as a signiﬁcant
problem in general adult psychiatry, and as an import-
ant differential diagnosis in this setting (Tebartz van
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Elst et al. 2013). Diagnosis of previously undetected
ASD in adults is therefore key to managing the dis-
order, yet as there are no reliable biomarkers for ASD
(Horder & Murphy, 2012), diagnosis relies on lengthy
and costly expert clinical assessments. The capacity of
adult ASD diagnostic services is, therefore, stretched.
In light of the fact that resource limitations can delay
or prevent individuals from receiving a needed ASD
assessment, it has been proposed that a means to
‘gate’ or triage referrals to such services is desirable.
In particular, the Autism-Spectrum Quotient (AQ), a
self-report questionnaire (Baron-Cohen et al. 2001),
has been suggested as a means of quickly and cost-
effectively estimating ASD risk and thus guiding refer-
rals. The UK National Institute for Health and Care
Excellence (NICE) recently endorsed the AQ for this
purpose (Woodbury-Smith et al. 2005; NICE, 2012).
NICE recommends that individuals with ‘possible aut-
ism’ should be offered a referral to a specialist diagnos-
tic service if they score above the threshold (6 or more
out of 10) on the AQ questionnaire.
However, it is not clear how well the AQ is suitable
for the role of referral screening. While the AQ has
been shown to discriminate well between individuals
with diagnosed ASD and healthy controls (Baron-
Cohen et al. 2001; Wakabayashi et al. 2006; Booth
et al. 2013), little is known about whether the AQ can
predict ASD diagnosis in adults with suspected ASD.
One previous study (Ketelaars et al. 2008) found that
the AQ was unable to predict ASD diagnosis within
a clinically suspected population, although the sample
size was small (21 ASD cases). Two other groups have
reported that the AQ’s performance in predicting ASD
diagnosis was excellent (Woodbury-Smith et al. 2005)
or fair (Sizoo et al. 2015). Yet no study to date has
examined whether other psychiatric disorders (co-
morbidities), such as anxiety or depression, act as con-
founds in the relationship between AQ scores and ASD
diagnosis. This is a limitation, since co-morbidities are
common in patients presenting for a diagnostic evalu-
ation. Nor is it known whether the AQ predicts scores
on the so-called ‘gold-standard’ (Baird et al. 2006) for-
mal diagnostic assessments for ASD, the Autism
Diagnostic Observation Schedule-Generic (ADOS-G)
or the Autism Diagnostic Interview-Revised (ADI-R).
Therefore, we conducted the present study in order
to, for the ﬁrst time, examine the performance of the
AQ questionnaire as a predictor of the outcome of an
expert clinical ASD assessment, and the ADOS and
ADI, in adults referred to a specialist diagnostic service
with possible ASD, who were also assessed for co-
morbidities. We studied a large sample of patients
seen at a specialist diagnostic referral service. We
examined the 10-item AQ10 version of the question-
naire (Booth et al. 2013), which is recommended in
the NICE guidelines, and also the original 50-item ver-
sion of the scale (AQ50). Our objective was to test the
suitability of the AQ for ASD screening in the context
prescribed by NICE.
Method
Recruitment
This study included 476 patients seen at the
Behavioural Genetics Clinic (BGC) at the Maudsley
Hospital in London, England. The BGC is a National
Specialist Centre that accepts referrals from across the
UK. The BGC offers a comprehensive psychiatric as-
sessment; however, the focus is on the diagnosis of
ASD, and the BGC only accepts referrals where the pri-
mary suspected diagnosis is ASD. The present sample
represents all of the patients seen (consecutive admis-
sions) at the BGC clinic over the period from
September 2009 to May 2013. This is because, in
September 2009 the BGC clinic added the AQ to the
clinical questionnaire pack sent to all patients before
their assessment, and in May 2013 the decision was
taken to begin the current analysis of the AQ data.
The only selection criteria were age 18+ years and giv-
ing informed consent. Over the period of this study,
primary care (general practitioners) accounted for
37.7% of the referrals to the BGC, tertiary care 52.9%,
and other sources 9.3%.
Screening measures (AQ questionnaire)
Screening measures included the brief AQ10 question-
naire, and the full-length AQ50. Participants com-
pleted the AQ50, and we derived AQ10 scores from
these answers, according to Allison et al. (2012).
AQ10 scores are calculated by summing the following
10 items from the AQ50 questionnaire: items 5, 20, 27,
28, 31, 32, 36, 37, 41 and 45. These items were selected
by Allison et al. (2012) on the basis that they best discri-
minated (i.e. have the highest discrimination index) be-
tween ASD patients and healthy controls. The original
Autism-Spectrum Quotient (AQ50) contains 50 ques-
tions, relating to social skill, attention switching, atten-
tion to detail, communication and imagination. Each
item has four possible responses (‘deﬁnitely agree’,
‘slightly agree’, ‘slightly disagree’, ‘deﬁnitely dis-
agree’). Respondents are instructed to select one re-
sponse per item. Items are scored dichotomously (i.e.
collapsing ‘deﬁnitely agree’ and ‘slightly agree’ into
‘agree’ and similarly for ‘disagree’), with one point
being assigned for each response characteristic of
ASD. Total AQ50 scores therefore range from 0 to 50,
with higher scores indicating more autistic traits. The
published cut-off value for the AQ10 is 56, i.e. scores
of 6 or above are considered positive for ASD (Allison
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et al. 2012). For the AQ50, we compared two previous-
ly described cut-offs: the ‘clinical’ threshold of 532
and the ‘screening’ cut-off of 526 (Baron-Cohen et al.
2001). All questionnaires were administered in English.
Additionally, we investigated a novel variant of the
AQ modiﬁed as an informant-rated scale. This meas-
ure, which has not been previously validated, was
introduced in the BGC clinic to explore its potential
as a non-self report measure of ASD symptoms and
difﬁculties. A family member or close friend of the par-
ticipant completed the informant AQ50. All of the
questions were taken from the original AQ but
re-worded to the gender-neutral third person. For ex-
ample, AQ50 item 1: ‘I prefer to do things with others
rather than on my own’ was changed to ‘S/he prefers to
do things with others rather than on his/her own’. The
informant AQ10 was derived in the same way as the
self-report version. All questionnaires were adminis-
tered in English.
ASD assessment
Two formal ASD assessments are used in the BGC ser-
vice: the ADOS-G (Lord et al. 2000) and the ADI-R
(Lord et al. 1994). Experienced clinicians or clinical re-
search workers administered these assessments. A clin-
ical expert judgement (diagnosis) was made.
The ADOS-G is a measure of current ASD symp-
toms. The assessment comprises a structured activity
session and semi-structured interview that includes a
series of social presses and other opportunities
intended to elicit behaviours associated with ASD.
ADOS-G module 4, designed for verbally ﬂuent ado-
lescents and adults, was used.
The ADI-R is a parent/primary caregiver interview
focused on developmental history of ASD-speciﬁc
behaviours. The ADI-R is a measure of early-life symp-
toms. Scores are aggregated into symptom clusters that
correspond to Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) criteria for a
diagnosis of autism (Lord et al. 1994).
Clinical diagnosis was made in a diagnostic meeting
by consensus amongst a multidisciplinary team, in-
cluding consultant psychiatrists, psychologists, psy-
chiatry senior house ofﬁcers (residents), specialist
nurses and clinical research workers, using Interna-
tional Classiﬁcation of Diseases (ICD)-10 research cri-
teria and informed by the patient’s ADOS-G and
ADI-R scores. For this study, any autism-spectrum
diagnosis was considered ‘ASD’, including diagnoses
of autism and Asperger’s syndrome.
Reﬂecting clinical practice at the BGC service, the
ADI-R was always performed ﬁrst if possible (i.e. if
the parent or caregiver was alive and willing to be
interviewed, and the patient provided consent for us
to speak with them). If the ADI-R could not be per-
formed, or if the outcome of the ADI-R was unclear,
the ADOS-G was completed. Therefore some patients
received an ADI-R only, some received an ADOS-G
only, and a minority received both an ADI-R and an
ADOS-G (these patients represented the more complex
cases.)
Sample size
A total of 476 adult patients were seen at the BGC clin-
ic during the period of the study. Self-rated AQ50
scores were available for 456 of these (96%) and
AQ10 scores were subsequently calculated for 428
(90%) (see online Supplementary Method). Of the
patients, 473 (99%) received a clinical consensus expert
diagnosis, 210 (44%) received an ADOS-G assessment,
305 (64%) received an ADI-R, of which 40 received
both ADOS-G and ADI-R. No a priori sample size cal-
culation was performed because these data were ori-
ginally collected for clinical purposes.
Supplementary information
For a further description of the assessment of other
psychiatric disorders (co-morbidities), the BGC assess-
ment procedures, data analysis and the treatment of
missing items, and inclusion and exclusion criteria,
please see the online Supplementary Method.
Ethical standards
All procedures contributing to this work comply with
the ethical standards of the relevant UK and institu-
tional guidelines and with the Helsinki Declaration of
1975, as revised in 2008. All participants provided
written consent to use outcome measures and clinical
data for research purposes, and the study was
approved by the National Research Ethics Service
(NRES) Ethics Committee London – South East (ref:
12/LO/0790).
Results
Study population
The sample of 476 adults included 355 males (75%) and
121 females (25%). Age ranged from 18 to 70 years,
with a median age of 29 years. Of the participants,
115 (24%) were aged 21 years or younger. Of the
patients, 346 (73%) were assigned a diagnosis of ASD
by the clinical team at the BGC (see Table 1).
The AQ10 as a predictor of ASD diagnosis
The AQ10, with a cut-off of 56, did not predict ASD
diagnosis better than chance [χ2 = 1.423, degrees of
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freedom (df) = 1, p = 0.233]. While the test showed high
sensitivity (0.77) as a predictor of receiving an ASD
diagnosis, its speciﬁcity was less good (0.29) (see
Table 2). The positive predictive value was high
(0.76), indicating that three-quarters of those scoring
56 on the AQ10 did receive a clinical diagnosis of
ASD. However, the low negative predictive value
(0.36) implies that nearly two-thirds of those who
scored below the56 AQ10 cut-off, predicted not to re-
ceive an ASD diagnosis, in fact were diagnosed with
ASD. For a post-hoc power analysis of these compari-
sons, see the online Supplementary Results.
We applied a receiver operating characteristic (ROC)
curve analysis to evaluate the performance of the
AQ10 with a range of cut-off criteria. The AQ10 did
not signiﬁcantly predict clinical diagnosis by this
criterion either [area under the curve (AUC) 0.55,
p = 0.12] (see online Supplementary Fig. S1).
Fig. 1 shows the distribution of AQ10 scores accord-
ing to ASD diagnosis status. There was no signiﬁcant
difference in mean AQ10 scores between those diag-
nosed with ASD and those without ASD (ASD mean
7.26, S.D. = 2.28; not-ASD mean 6.85, S.D. = 2.46, t test,
p = 0.12), conﬁrming that AQ10 scores are not predict-
ive of clinical diagnosis.
Comparison of the AQ10 and AQ50 questionnaires
In a secondary analysis, we examined whether the ori-
ginal AQ50 questionnaire predicts ASD caseness better
than the brief AQ10 (see Table 2). Applying the
‘screening’ cut-off of526, the AQ50 performed signiﬁ-
cantly better than chance (χ2 = 3.976, df = 1, p = 0.046).
However, its predictive power was modest, including
high sensitivity (0.88) but very low speciﬁcity (0.20).
At the higher ‘clinical’ cut-off of AQ50 532, perform-
ance was no better than chance (χ2 = 1.265, df = 1, p =
0.261).
Table 1. Patient characteristics
Measure
Gender, n (%)
Male 355 (75)
Female 121 (25)
Mean age, years (S.D.) 32.3 (11.4)
Mean AQ10 (S.D.) 7.2 (2.3)
Mean AQ50 (S.D.) 34.9 (8.2)
Clinical ASD diagnosis, n (%)
Positive 346 (73)
Negative 126 (27)
S.D., Standard deviation; AQ, Autism-Spectrum Quotient;
ASD, autism spectrum disorder.
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Comparison of the AQ informant-report and
self-report
The performance of the informant-report AQ50 and
AQ10 was similar to that of the self-report versions
of the scale (see Table 2). The AQ10 (χ2 = 3.658, df =
1, p = 0.056) and AQ50 cut-off 526 (χ2 = 3.785, df = 1,
p = 0.052) both predicted caseness marginally better
than chance. The AQ50 cut-off 532 was signiﬁcantly
superior to chance (χ2 = 8.860, df = 1, p = 0.003), but
even here the speciﬁcity was poor (0.38). In the
ROC curve analysis of the informant-report AQ50
and AQ10, these measures performed very similarly
to the self-report versions. The informant AQ50,
though not the AQ10, predicted clinical diagnosis
slightly better than chance (AUC 0.58, p = 0.017), simi-
larly to the self-report AQ50 (where the AUC was
0.56). The best performance was with a cut-off of
532 at which there was a sensitivity of 0.78 and a
speciﬁcity of 0.38, and an accuracy of 67% (see online
Supplementary Fig. S2).
Correlations between AQ and the ADOS-G and
ADI-R
In order to address the question of whether AQ scores
are predictive of the severity of ASD symptoms as con-
tinuous variables, we examined Pearson product-
moment correlations between AQ scores and total
scores on the ADOS-G and the ADI-R. ADOS-G totals
were the sum of the communication, social, and repeti-
tive/restricted behaviours domains. ADI-R totals were
the sum of the communication, social, and repetitive
domains. ADOS-G totals were not correlated with
either the self-report AQ10 or the AQ50 (all p > 0.2).
In contrast, ADI-R totals were correlated with the self-
report AQ10 (r = 0.12, p = 0.045) and the AQ50 (r = 0.13,
p = 0.030), albeit weakly (see Table 3). These results
show that self-reported ASD traits, measured using
the AQ, are not correlated with clinician-rated current
ASD behaviours (ADOS-G), but are weakly associated
with retrospectively reported early-life ASD symptoms
(ADI-R). The correlation between ADOS-G and ADI-R
scores was of trend signiﬁcance (r = 0.29, p = 0.072,
n = 40).
Associations between psychiatric disorders
(co-morbidities) and AQ scores
We obtained data on co-morbidities for 396 patients
(84% of the sample). Across the whole sample, major
depressive disorder was present in 20% of cases,
panic/agoraphobia 12%, generalized anxiety disorder
(GAD) 20%, social anxiety/phobia 17%, attention-
deﬁcit/hyperactivity disorder 16%, and obsessive–
compulsive disorder 20%. Overall, 69% of patients
were diagnosed with one or more co-morbidities (see
Table 4).
Compared with true negatives (who scored <6 on
the AQ10 and did not receive a clinical ASD diagno-
sis), false positives (<6 on the AQ10 but did receive a
diagnosis) were more likely to have GAD (21.1% v.
3.7%, χ2 = 4.347, df = 1, p = 0.037). This suggests that
GAD might ‘mimic’ ASD and lead to false positives
on the AQ. In contrast, false negatives were less likely
to have at least one co-morbidity than true positives
Fig. 1. Distribution of 10-item Autism-Spectrum Quotient (AQ10) scores in patients according to whether they subsequently
received a clinical diagnosis of autism spectrum disorder (ASD). (a) Histograms showing the proportion of patients who did
not receive an ASD diagnosis (left) and of those who did receive a diagnosis (right) scoring at each level on the AQ10 (score
out of 10). (b) Proportion of those scoring at each level of the AQ10 who received an ASD diagnosis. Values are means, with
standard errors (s.e.m.) represented by horizontal bars. For a colour ﬁgure, see the online version.
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(61.0% v. 76.1%, χ2 = 5.241, df = 1, p = 0.022). This sug-
gests that individuals with ‘pure’ ASD, and no co-
morbidities, might be more likely to be missed by the
AQ questionnaire. See Table 4 for co-morbidity rates
for each of the four groups (true positive, false positive,
true negative, and false negative).
Table 3. Correlations amongst AQ scores, and total ADOS-G (communication + social + repetitive/restricted behaviours) and total ADI-R
scoresa
Self-report AQ50 Self-report AQ10 Informant AQ50 Informant AQ10 ADOS-G total ADI-R total
Self-report AQ50
r 1 0.82** 0.56** 0.33** 0.06 0.13*
p <0.001 <0.001 <0.001 0.433 0.030
n 428 364 340 204 290
Self-report AQ10
r 1 0.47** 0.43** −0.05 0.12*
p <0.001 <0.001 0.459 0.045
n 341 321 194 271
Informant AQ50
r 1 0.74** 0.038 0.37**
p <0.001 0.644 <0.001
n 358 153 260
Informant AQ10
r 1 −0.05 0.29**
p 0.583 <0.001
N 141 245
ADOS-G total
r 1 0.29
p 0.072
n 40
ADI-R total
r 1
p
n
AQ, Autism-Spectrum Quotient; ADOS-G, Autism Diagnostic Observation Schedule-Generic; ADI-R, Autism Diagnostic
Interview-Revised; AQ50, 50-item AQ; AQ10, 10-item AQ.
a All correlation coefﬁcients are bivariate Pearson’s r. p Values are two-tailed. The number of observations (n) for each com-
parison varies because not all participants underwent all assessments.
Correlation signiﬁcant: * p < 0.05, ** p < 0.001.
Table 4. Rates of co-morbidities in true and false positives, and true and false negatives, with caseness deﬁned by ASD clinical diagnosis and
screening prediction of ASD deﬁned as AQ10 self-report scores of56
Rate of disorder in
AQ10 true positives
(n = 201)
Rate of disorder in
AQ10 false positives
(n = 71)
Rate of disorder in
AQ10 true negatives
(n = 27)
Rate of disorder in
AQ10 false negatives
(n = 59)
Depression, % 21.9 21.1 14.8 18.6
Panic/agoraphobia, % 17.9 2.8 7.4 10.2
Generalized anxiety disorder, % 24.9 21.1 3.7 15.3
Social anxiety, % 18.4 16.9 14.8 15.3
Attention-deﬁcit/hyperactivity
disorder, %
15.9 14.1 22.2 11.9
Obsessive–compulsive disorder, % 26.9 9.9 14.8 13.6
Any co-morbidity, % 76.1 57.8 66.7 61.0
ASD, Autism spectrum disorder; AQ10, 10-item Autism-Spectrum Quotient.
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To discover whether co-morbidities predict AQ
scores independent of ASD caseness, we performed a
general linear model (GLM) analysis with AQ10 scores
as the dependent variable. Independent variables
(ﬁxed-effect factors) were: clinical ASD diagnosis,
and the six co-morbidities as binary predictors. The
GLM revealed that GAD (p = 0.014) was the only sign-
iﬁcant predictor of AQ10 scores, while ASD diagnosis
did not predict AQ10 scores (p = 0.537) in this analysis.
See online Supplementary Table S1 for the full GLM
results. The AQ questionnaire therefore seems to be
more sensitive to the presence of GAD than it is to
ASD in this sample. Those individuals with ASD
who present with no psychiatric co-morbidities may
be at risk of scoring below threshold on the AQ and
thus becoming false negatives if the AQ is used as a
screening tool.
Financial implications of using the AQ to triage
referrals
In order to put these results into a ﬁnancial context, we
estimated the ﬁnancial implications had the BGC clinic
adopted the NICE guidelines suggesting that referrals
for ASD assessment should be made for a score of
56 on the AQ10. This does not represent a comprehen-
sive health economics analysis, as we do not attempt to
estimate the value of receipt of an ASD diagnosis to an
adult with ASD, or the cost to society of a case of un-
diagnosed ASD.
In our sample of consecutive BGC patients spanning
4 years, 102 (24%) scored 5 or below on the AQ10.
Given that each BGC assessment costs the National
Health Service (NHS) £2305 on average, according to
a 2011 estimate (Murphy et al. 2011), this implies that
a total of £ 235 110 (102 × £2305) could have been
saved if all of these ‘AQ10 negative’ individuals had
not received a BGC referral, assuming that all other
factors remained equal. However, 71 of those 102 refer-
rals went on to receive a clinical diagnosis of ASD at
the BGC, that is, 70% of the ‘negatives’ proved to be
false negatives. Therefore, for every 10 patients denied
a referral, £ 23 050 would have been saved but seven
ASD cases would go undiagnosed. For every £3300
(£ 235 000/71) saved, an individual with ASD would
miss out on a diagnosis.
Regarding the issue of false positives, of the 425
referrals, 323 (76%) scored 6 or above on the AQ10
and would have been offered a referral under the
NICE guidelines. However, of these 323, 79 (24%)
were diagnosed as not having an ASD at the clinical
assessment. As each assessment costs £2305, these
false positives on the AQ10 would have cost the
NHS £ 182 095 (79 x £2305) over the 4 years of the
study, or about £ 45 000 per year. Some of these
patients may have beneﬁted from their BGC assess-
ment despite not receiving an ASD diagnosis, e.g.
by receiving a diagnosis of another psychiatric dis-
order. However, 30 of the 79 (38%) AQ10 ‘false posi-
tives’ were not assessed as having any psychiatric
disorder.
Discussion
We investigated the AQ questionnaire as a predictor of
ASD caseness in a large sample of adults referred to
our diagnostic clinic with suspected ASD. Our object-
ive was to determine if the AQ would be an effective
means of ‘gating’ clinical referrals, as recommended
by the UK NICE guidelines (NICE, 2012). We found lit-
tle evidence that the AQ could predict who would re-
ceive a clinical diagnosis of ASD in our sample. The
brief AQ10 questionnaire was no better than chance
as a predictor of ASD diagnosis, providing high sensi-
tivity (0.77) but low speciﬁcity (0.29). Nearly two-thirds
of the patients who scored below the cut-off score of 6
were ‘false negatives’, i.e. they went on to receive a
diagnosis of ASD. The longer version of the question-
naire, the AQ50, performed only marginally better.
These results contrast with some prior ﬁndings. In
two large studies (Allison et al. 2012; Booth et al.
2013), the AQ10 was found to discriminate well be-
tween ASD adults and healthy controls. However,
Brugha et al. (2011b) found that it only modestly pre-
dicted ASD caseness within a large general population
sample. In that study, the AQ had a sensitivity of 0.73
and a speciﬁcity of 0.62 when acting as a predictor of
scoring above the threshold of 10 points on the
ADOS-G, and AQ scores were signiﬁcantly, but weak-
ly, correlated with ADOS-G total symptoms (r = 0.24).
In our sample we found a comparable sensitivity, but
a substantially lower speciﬁcity, and no signiﬁcant cor-
relation between the ADOS-G and the AQ.
Why does the ability of the AQ to predict ASD diag-
nosis vary across studies? One plausible explanation is
differences in the nature of the non-ASD group. The
AQ shows excellent performance (Allison et al. 2012;
Booth et al. 2013) in distinguishing ASD cases from
healthy controls recruited from the general population.
However, such case–control studies are known to over-
estimate the accuracy of diagnostic tests (Lijmer et al.
1999; Rutjes et al. 2006). Our study did not use a
case–control design, and our results suggest that the
AQ differentiates poorly between true cases of ASD,
and individuals from the same clinical population
who do not have ASD (Simonoff et al. 2008; Freeth
et al. 2012; L Underwood et al., unpublished observa-
tions). Furthermore, we show that scores on the AQ
were not correlated with current ASD symptoms as
measured with the ADOS-G. AQ scores did predict
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scores on the ADI-R, a retrospective measure of child-
hood symptoms, but only weakly.
If the AQ, in its current form, is poorly predictive of
ASD diagnosis in a clinical setting, why is this? One
possible explanation is that individuals with ASD
lack insight into their own behaviour (Bishop &
Seltzer, 2012) and so ﬁnd it difﬁcult to self-report
their own symptoms. However, against this hypoth-
esis, we found that even when an informant completed
the AQ, scores only marginally predicted clinical diag-
nosis, and did not correlate with ADOS-G symptoms.
While the informant AQ was more predictive of
ADI-R scores, this may reﬂect the fact that the ADI-R
is itself an informant measure and the same informant
completed both.
Therefore, a lack of self-insight may not fully account
for the frequent discrepancies between the AQ and
other ASD measures. Co-morbidities may go some
way to explain this issue. We found that the presence
of ASD is not an independent predictor of AQ10 scores
but GAD does predict higher AQ10 scores. Thus, GAD
may contribute to false positives. We speculate that the
AQ may be sensitive to anxiety because several AQ
items take the form of self-evaluations, e.g. ‘I ﬁnd it
difﬁcult to work out people’s intentions’. Anxious indi-
viduals commonly lack conﬁdence in their social abil-
ities (Mathews & MacLeod, 2005) and it is possible
that this low self-esteem might manifest as ASD-
typical answers. Clinicians performing an ASD assess-
ment, however, are able to use their judgement to
distinguish between ASD and other conditions that
can mimic ASD symptoms. We also showed that
ASD individuals without co-morbidities tended to
score low on the AQ, perhaps putting them at risk of
becoming ‘false negative’ cases, those who had ASD
but scored <6 on the AQ10.
Our results have implications for both clinical ser-
vices and for future research. From a clinical perspec-
tive, we suggest that the adoption of the AQ as a
clinical tool (as recommended by NICE) (NICE, 2012)
will need to be guided by an assessment of the costs
and beneﬁts in relation to the particular patient popu-
lation in which its use is proposed. We have shown
that, in a population with suspected ASD seen at a na-
tional specialist diagnostic clinic, the sensitivity of the
AQ is acceptable, but the speciﬁcity is poor, and the
overall performance is little better than chance. As
regards implications for future research, our ﬁndings
highlight the need for measures of ASD symptoms
that are suitable for use in the population with sus-
pected ASD. It is possible that a subset of AQ50
items might be more effective than the AQ50 or the
AQ10 subset that we examined. Alternatively, another
ASD trait questionnaire might prove more suitable, for
instance the Autism Spectrum Disorders in Adults
Screening Questionnaire (ASDASQ) (Nylander &
Gillberg, 2001). Finally, a novel scale more predictive
of ASD diagnosis might be developed through a
study of how clinicians discriminate ASD from
‘ASD-like’ symptoms.
Our study has a number of limitations. First, our
study population was limited to one clinic, the BGC,
which is a national referral centre. It remains to be
determined how well our results would generalize to
other clinical services. It is possible, for instance, that
the AQ might perform better in screening the referrals
received by smaller local ASD services, which receive a
higher proportion of referrals from primary and sec-
ondary care. Future research should explore this possi-
bility. Next, a limitation of this retrospective study was
that we did not produce a published study protocol,
and no a priori power calculations were performed.
This was a retrospective analysis, rather than a pro-
spective study designed to address a particular ques-
tion. A further limitation is that we did not obtain
intelligence quotient (IQ) scores for our participants.
IQ has been shown to correlate with AQ scores
(Bishop & Seltzer, 2012) but may be negatively asso-
ciated with ADOS severity (Klin et al. 2007); therefore
it would have been desirable to measure IQ as a poten-
tial confound. Similarly, while we had qualitative mea-
sures of psychiatric co-morbidity, i.e. ICD-10
diagnoses, we lacked continuous measures of the se-
verity of these symptoms and so could not address
these as confounds in a quantitative manner. We calcu-
lated the AQ10 scores by summing the appropriate
items from the AQ50, rather than by administering
the AQ10 as a questionnaire per se. It is possible that
our results would be different had we done so. A
ﬁnal limitation is that we only examined the
ADOS-G and ADI-R as ASD diagnostic tools, and
did not evaluate other instruments, such as the
Diagnostic Interview for Social and Communication
Disorders schedule (Wing et al. 2002).
In conclusion, we report that the AQ did not predict
ASD caseness in a large sample of patients seen at an
adult ASD diagnostic service. Therefore, the utility of
the AQ for triaging ASD referrals in those with sus-
pected ASD is called into question. Being diagnosed
with ASD can represent a turning point for patients –
and 85% of UK adults diagnosed with an ASD were
glad to receive the diagnosis (Jones et al. 2014). These
results suggest that, in the diagnosis of ASD, self-
report questionnaire measures may not yet be able to
substitute for specialist clinical assessments.
Supplementary material
For supplementary material accompanying this paper
visit http://dx.doi.org/10.1017/S0033291716001082
2602 K. L. Ashwood et al.
https://doi.org/10.1017/S0033291716001082
Downloaded from https://www.cambridge.org/core. EBSCO Industries Inc, on 23 Aug 2018 at 10:45:53, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
Acknowledgements
The ﬁrst three authors, K.L.A., N.G. and J.H., contribu-
ted equally to this work. We are extremely grateful to all
the individuals and families who took part in the stud-
ies. Thanks also to Hanna Clarke, Michael Craig,
Haraldur Erlendsson and Deirdre Howley for their
help. Special thanks to everyone at the BGC. Parts of
this work were presented at the International Meeting
for Autism Research (IMFAR) 2013 in San Sebastian,
Spain and at IMFAR 2014 in Atlanta, GA, USA. This
work was supported by a National Institute for Health
Research (NIHR) programme grant (RP-PG-0606-1045),
by the BGC as well as by the European Union via the
EU-AIMS consortium. J.H. was supported by the
Wellcome Trust and by the Biomedical Research
Centre (BRC) at King’s College London. D.G.M was
supported by the Dr Mortimer D. Sackler Foundation.
P.B was supported by an NIHR Senior Investigator
award and the BRC in Mental Health at the South
London and Maudsley NHS Trust. C.E.W receives post-
doctoral research funding via the Marie Curie Action,
co-ﬁnanced by the Junta de Andalucía and the
European Commission under Talentia Postdoc grant
number 267 226. The authors acknowledge ﬁnancial
support from the Department of Health via the NIHR
BRC and Dementia Unit awarded to South London
and Maudsley NHS Foundation Trust, in partnership
with King’s College London and King’s College
Hospital NHS Foundation Trust. This work was sup-
ported by EU-AIMS (European Autism Interventions),
which receives support from the Innovative Medicines
Initiative Joint Undertaking under grant agreement no.
115300, the resources of which are composed of ﬁnancial
contributions from the European Union’s Seventh
Framework Programme (grant FP7/2007-2013), from
the European Federation of Pharmaceutical Industries
and Associations companies’ in-kind contributions,
and from Autism Speaks.
Declaration of Interest
None.
References
Allison C, Auyeung B, Baron-Cohen S (2012). Toward brief
“red ﬂags” for autism screening: the Short Autism
Spectrum Quotient and the Short Quantitative Checklist in
1,000 cases and 3,000 controls. Journal of the American
Academy of Child and Adolescent Psychiatry 51, 202–212e7.
Baird G, Simonoff E, Pickles A, Chandler S, Loucas T,
Meldrum D, Charman T (2006). Prevalence of disorders of
the autism spectrum in a population cohort of children in
South Thames: the Special Needs and Autism Project
(SNAP). Lancet 368, 210–215.
Baron-Cohen S, Scott FJ, Allison C, Williams J, Bolton P,
Matthews FE, Brayne C (2009). Prevalence of
autism-spectrum conditions: UK school-based population
study. British Journal of Psychiatry 194, 500–509.
Baron-Cohen S, Wheelwright S, Skinner R, Martin J,
Clubley E (2001). The Autism-Spectrum Quotient (AQ):
evidence from Asperger syndrome/high-functioning
autism, males and females, scientists and mathematicians.
Journal of Autism and Developmental Disorders 31, 5–17.
Bishop SL, Seltzer MM (2012). Self-reported autism
symptoms in adults with autism spectrum disorders.
Journal of Autism and Developmental Disorders 42, 2354–2363.
Booth T, Murray AL, McKenzie K, Kuenssberg R, O’Donnell
M, Burnett H (2013). Brief report: an evaluation of the AQ-10
as a brief screening instrument for ASD in adults. Journal of
Autism and Developmental Disorders 43, 2997–3000.
Brugha TS,McManus S, Bankart J, Scott F, Purdon S, Smith J,
Bebbington P, Jenkins R, Meltzer H (2011a).
Epidemiology of autism spectrum disorders in adults in the
community in England. Archives of General Psychiatry 68,
459–465.
Brugha TS, McManus S, Smith J, Scott FJ, Meltzer H,
Purdon S, Berney T, Tantam D, Robinson J, Radley J,
Bankart J (2011b). Validating two survey methods for
identifying cases of autism spectrum disorder among adults
in the community. Psychological Medicine 42, 647–656.
Buescher AV, Cidav Z, Knapp M, Mandell DS (2014). Costs
of autism spectrum disorders in the United Kingdom and
the United States. JAMA Pediatrics 168, 721–728.
Developmental Disabilities Monitoring Network
Surveillance Year 2010 Principal Investigators; Centers for
Disease Control and Prevention (CDC) (2014). Prevalence
of autism spectrum disorders among children aged 8
years – Autism and Developmental Disabilities Monitoring
Network, 11 sites, United States, 2010. MMWR Surveillance
Summaries 63, 1–22.
Freeth M, Bullock T, Milne E (2012). The distribution of and
relationship between autistic traits and social anxiety in a
UK student population. Autism 17, 571–581.
Geurts HM, Jansen MD (2012). A retrospective chart study:
the pathway to a diagnosis for adults referred for ASD
assessment. Autism 16, 299–305.
Horder J, Murphy DG (2012). Recent advances in
neuroimaging in autism. Cognitive Neuropsychiatry 2,
221–229.
Jones L, Goddard L, Hill EL, Henry LA, Crane L (2014).
Experiences of receiving a diagnosis of autism spectrum
disorder: a survey of adults in the United Kingdom. Journal
of Autism and Developmental Disorders 44, 3033–3044.
Ketelaars C, Horwitz E, Sytema S, Bos J, Wiersma D,
Minderaa R, Hartman CA (2008). Brief report: adults with
mild autism spectrum disorders (ASD): scores on the
Autism Spectrum Quotient (AQ) and comorbid
psychopathology. Journal of Autism and Developmental
Disorders 38, 176–180.
Klin A, Saulnier CA, Sparrow SS, Cicchetti DV, Volkmar
FR, Lord C (2007). Social and communication abilities and
disabilities in higher functioning individuals with autism
spectrum disorders: the Vineland and the ADOS. Journal of
Autism and Developmental Disorders 37, 748–759.
Predicting the diagnosis of autism using the Autism-Spectrum Quotient questionnaire 2603
https://doi.org/10.1017/S0033291716001082
Downloaded from https://www.cambridge.org/core. EBSCO Industries Inc, on 23 Aug 2018 at 10:45:53, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
Koegel LK, Koegel RL, Ashbaugh K, Bradshaw J (2014). The
importance of early identiﬁcation and intervention for
children with or at risk for autism spectrum disorders.
International Journal of Speech and Language Pathology 16, 50–56.
Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH,
van der Meulen JH, Bossuyt PM (1999). Empirical
evidence of design-related bias in studies of diagnostic tests.
JAMA 282, 1061–1066.
Lord C, Risi S, Lambrecht L, Cook Jr. EH, Leventhal BL,
DiLavore PC, Pickles A, Rutter M (2000). The Autism
Diagnostic Observation Schedule-Generic: a standard
measure of social and communication deﬁcits associated
with the spectrum of autism. Journal of Autism and
Developmental Disorders 30, 205–223.
Lord C, Rutter M, Le Couteur A (1994). Autism Diagnostic
Interview-Revised: a revised version of a diagnostic
interview for caregivers of individuals with possible
pervasive developmental disorders. Journal of Autism and
Developmental Disorders 24, 659–685.
Mathews A, MacLeod C (2005). Cognitive vulnerability to
emotional disorders. Annual Review of Clinical Psychology 1,
167–195.
Murphy DG, Beecham J, Craig M, Ecker C (2011). Autism in
adults. New biologicial ﬁndings and their translational
implications to the cost of clinical services. Brain Research
1380, 22–33.
NICE (2012). Autism: Recognition, Referral, Diagnosis and
Management of Adults on the Autism Spectrum. NICE
Clinical Guideline CG142. National Institute for Clinical
Excellence: London (https://www.nice.org.uk/guidance/
cg142). Accessed June 2016.
Nylander L, Gillberg C (2001). Screening for autism spectrum
disorders in adult psychiatric out-patients: a preliminary
report. Acta Psychiatrica Scandinavica 103, 428–434.
Nylander L, Holmqvist M, Gustafson L, Gillberg C (2013).
Attention-deﬁcit/hyperactivity disorder (ADHD) and autism
spectrum disorder (ASD) in adult psychiatry. A 20-year
register study. Nordic Journal of Psychiatry 67, 344–350.
Rutjes AW, Reitsma JB, Di Nisio M, Smidt N, van Rijn JC,
Bossuyt PM (2006). Evidence of bias and variation in
diagnostic accuracy studies. CMAJ 174, 469–476.
Simonoff E, Pickles A, Charman T, Chandler S, Loucas T,
Baird G (2008). Psychiatric disorders in children with
autism spectrum disorders: prevalence, comorbidity, and
associated factors in a population-derived sample. Journal of
the American Academy of Child and Adolescent Psychiatry 47,
921–929.
Sizoo BB, Horwitz EH, Teunisse JP, Kan CC, Vissers C,
Forceville E, Van Voorst A, Geurts HM (2015). Predictive
validity of self-report questionnaires in the assessment of
autism spectrum disorders in adults. Autism 19, 842–849.
Tebartz van Elst L, Pick M, Biscaldi M, Fangmeier T, Riedel
A (2013). High-functioning autism spectrum disorder as a
basic disorder in adult psychiatry and psychotherapy:
psychopathological presentation, clinical relevance and
therapeutic concepts. European Archives of Psychiatry and
Clinical Neurosciences 263, 189–196.
Wakabayashi A, Baron-Cohen S, Wheelwright S, Tojo Y
(2006). The Autism-Spectrum Quotient (AQ) in Japan: a
cross-cultural comparison. Journal of Autism and
Developmental Disorders 36, 263–270.
Wing L, Leekam SR, Libby SJ, Gould J, Larcombe M (2002).
The Diagnostic Interview for Social and Communication
Disorders: background, inter-rater reliability and clinical
use. Journal of Child Psychology and Psychiatry 43, 307–325.
Woodbury-Smith MR, Robinson J, Wheelwright S,
Baron-Cohen S (2005). Screening adults for Asperger
syndrome using the AQ: a preliminary study of its
diagnostic validity in clinical practice. Journal of Autism and
Developmental Disorders 35, 331–335.
Youden WJ (1950). Index for rating diagnostic tests. Cancer 3,
32–35.
2604 K. L. Ashwood et al.
https://doi.org/10.1017/S0033291716001082
Downloaded from https://www.cambridge.org/core. EBSCO Industries Inc, on 23 Aug 2018 at 10:45:53, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
